• Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10

    ソース: Nasdaq GlobeNewswire / 07 8 2023 08:00:01   America/New_York

    NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the Company will release financial results for the second quarter ended June 30, 2023 on Thursday, August 10, 2023, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. EDT to review the financial and operating results.

    Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) and referencing conference ID 13739696.

    To access the Call me™ feature, which avoids having to wait for an operator, click here.

    A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.

    After the live webcast, the event will be archived on Eyenovia’s website for one year.

    About Eyenovia, Inc.

    Eyenovia, Inc. (NASDAQ: EYEN) is a commercial stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide + phenylephrine ophthalmic spray) for mydriasis, as well as the ongoing late-stage development of medications in the Optejet device for presbyopia and myopia progression (partnered with Bausch+Lomb). For more information, visit Eyenovia.com.

    The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

    Eyenovia Contact:
    Eyenovia, Inc.
    John Gandolfo
    Chief Financial Officer
    jgandolfo@eyenovia.com

    Eyenovia Investor Contact:
    Eric Ribner
    LifeSci Advisors, LLC
    eric@lifesciadvisors.com
    (646) 751-4363

    Eyenovia Media Contact:
    Eyenovia, Inc.
    Norbert Lowe
    Vice President, Commercial Operations
    nlowe@eyenovia.com



    Primary Logo

シェアする